Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189 trial, providing thoughts on the clinical implications of these findings in management of this patient subset.
KEYNOTE-189: Clinical Implications in Patients with Advanced Non-Squamous NSCLC and Low (1-49%) Tumor PD-L1 Expression (BMIC-032)
